Hydroxyprogesterone Caproate

己酸羟孕酮

Report date: 2026/03/13 20:02:36
NME

Base Information

Drug NameHydroxyprogesterone Caproate
Drug Alias Name羟基孕酮己酸盐Hydroxyprogesterone caproate长效黄体酮Hydroxyprogesterone long-actingcaproato de hidroxiprogesterona +[23] 
ClassificationSmall molecules > Steroids
Mechanisms of ActionProgesterone receptor agonists
TargetsProgesterone receptor
Therapy Area/IndicationsPainMenstruation DisturbancesPremature Birth +[9] 
Global Approved IndicationsMenstruation DisturbancesObstetric Labor, PrematureUterine Hemorrhage +[4] 
Approved Indications in ChinaMenstruation DisturbancesObstetric Labor, PrematureUterine Hemorrhage +[4] 
Original Approved Country/TerritoryUnited States
Original Approved Date1974/12/26
Country/TerritoryCzechiaBulgariaCanada +[13] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Mississippi Medical CenterUniversity Of South FloridaHuazhong Pharmaceutical Co Ltd
Inactive CompaniesObstetrix Medical GroupEunice Kennedy Shriver National Institute Of Child Health And Human DevelopmentStanford University +[9] 
Active IndicationsMenstruation DisturbancesPremature BirthObstetric Labor, Premature +[6] 
Inactive IndicationsPainPregnancy ComplicationsHIV Infections

Other Information

ATC CodeG03DA03
Related LinksWikipediaDrugBankKEGG